Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma
The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Bortezomib, lenalidomide, and dexamethasone (VRd) is a preferred first-line treatment option for patients with newly diagnosed multiple myeloma. Whether the addition of the anti-CD38 monoclonal antibody isatuximab to the VRd regimen would reduce the risk of disease progression or death among patients ineligible to undergo transplantation is unclear. METHODS: In an international, open-label, phase 3 trial, we randomly assigned, in a 3:2 ratio, patients 18 to 80 years of age with newly diagnosed multiple myeloma who were ineligible to undergo transplantation to receive either isatuximab plus VRd or VRd alone. The primary efficacy end point was progression-free survival. Key secondary end points included a complete response or better and minimal residual disease (MRD)-negative status in patients with a complete response. RESULTS: A total of 446 patients underwent randomization. At a median follow-up of 59.7 months, the estimated progression-free survival at 60 months was 63.2% in the isatuximab-VRd group, as compared with 45.2% in the VRd group (hazard ratio for disease progression or death, 0.60; 98.5% confidence interval, 0.41 to 0.88; P<0.001). The percentage of patients with a complete response or better was significantly higher in the isatuximab-VRd group than in the VRd group (74.7% vs. 64.1%, P = 0.01), as was the percentage of patients with MRD-negative status and a complete response (55.5% vs. 40.9%, P = 0.003). No new safety signals were observed with the isatuximab-VRd regimen. The incidence of serious adverse events during treatment and the incidence of adverse events leading to discontinuation were similar in the two groups. CONCLUSIONS: Isatuximab-VRd was more effective than VRd as initial therapy in patients 18 to 80 years of age with newly diagnosed multiple myeloma who were ineligible to undergo transplantation. (Funded by Sanofi and a Cancer Center Support Grant; IMROZ ClinicalTrials.gov number, NCT03319667.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Isatuximab plus VRd (Isa-VRd) has also shown impressive results in newly diagnosed myeloma.102,103”
From Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management (2024) · cites this paper as [102]
Citations
Cites
1 retracted
Jiang, H., Acharya, C., An, G., Zhong, M., Feng, X., Wang, L., Dasilva, N., Song, Z., Yang, G., Adrian, F., et al. (2016) · Leukemia · doi:10.1038/leu.2015.240 · Cited by 219
RetractedKumar, S., Paiva, B., Anderson, K. C., Durie, B., Landgren, O., Moreau, P., Munshi, N., Lonial, S., Bladé, J., Mateos, M.-V., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30206-6 · Cited by 3,061
Self-citationDaratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma
Facon, T., Kumar, S., Plesner, T., Orlowski, R. Z., Moreau, P., Bahlis, N., Basu, S., Nahi, H., Hulin, C., Quach, H., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1817249 · Cited by 1,045
Self-citationDaratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma
Mateos, M.-V., Dimopoulos, M. A., Cavo, M., Suzuki, K., Jakubowiak, A., Knop, S., Doyen, C., Lucio, P., Nagy, Z., Kaplan, P., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1714678 · Cited by 988
Self-citationMoreau, P., Attal, M., Hulin, C., Arnulf, B., Belhadj, K., Benboubker, L., Béné, M. C., Broijl, A., Caillon, H., Caillot, D., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31240-1 · Cited by 967
Self-citationDurie, B. G. M., Hoering, A., Abidi, M. H., Rajkumar, S. V., Epstein, J., Kahanic, S. P., Thakuri, M., Reu, F., Reynolds, C. M., Sexton, R., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(16)31594-x · Cited by 908
Self-citationMultiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†
Dimopoulos, M. A., Moreau, P., Terpos, E., Mateos, M. V., Zweegman, S., Cook, G., Delforge, M., Hájek, R., Schjesvold, F., Cavo, M., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2020.11.014 · Cited by 900
Self-citationMultiple myeloma: 2022 update on diagnosis, risk stratification, and management
Rajkumar, S. V. (2022) · American Journal of Hematology · doi:10.1002/ajh.26590 · Cited by 883
Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Myeloma
Benboubker, L., Dimopoulos, M. A., Dispenzieri, A., Catalano, J., Belch, A. R., Cavo, M., Pinto, A., Weisel, K., Ludwig, H., Bahlis, N., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402551 · Cited by 793
Self-citationDaratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.
Sonneveld, P., Dimopoulos, M. A., Boccadoro, M., Quach, H., Ho, P. J., Beksac, M., Hulin, C., Antonioli, E., Leleu, X., Mangiacavalli, S., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2312054 · Cited by 599
Self-citation
Cited by
Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management
Rajkumar, S. V. (2024) · American Journal of Hematology · doi:10.1002/ajh.27422 · Cited by 534
CAR-T cell therapy for cancer: current challenges and future directions
Zugasti, I., Espinosa-Aroca, L., Fidyt, K., Mulens-Arias, V., Diaz-Beya, M., Juan, M., Urbano-Ispizua, Á., Esteve, J., Velasco-Hernandez, T., & Menéndez, P. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02269-w · Cited by 281
Dimopoulos, M. A., Terpos, E., Boccadoro, M., Moreau, P., Mateos, M.-V., Zweegman, S., Cook, G., Engelhardt, M., Delforge, M., Hajek, R., et al. (2025) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-025-01041-x · Cited by 165
“75 .”
Self-citationUsmani, S. Z., Facon, T. T. F., Hungria, V., Bahlis, N. J., Venner, C. P., Braunstein, M. J., Pour, L., Martí, J. M., Basu, S., Cohen, Y. C., et al. (2025) · Nature Medicine · doi:10.1038/s41591-024-03485-7 · Cited by 207
“The median Daratumumab is a human immunoglobulin (Ig)Gκ monoclonal antibody targeting CD38 with direct on-tumor 1–4 and immunomodulatory 5–7 mechanisms of action that has demonstrated overall survival benefit in three frontline regimens 8–10 and was the first anti-CD38 monoclonal antibody approved in newly diagnosed m…”
InfluentialSelf-citationDaratumumab or active monitoring for high-risk smoldering multiple myeloma
Dimopoulos, M. A., Voorhees, P. M., Schjesvold, F., Cohen, Y. C., Hungria, V., Sandhu, I., Lindsay, J., Baker, R. I., Suzuki, K., Kosugi, H., et al. (2025) · New England Journal of Medicine · doi:10.1056/nejmoa2409029 · Cited by 121
Self-citationMai, E. K., Bertsch, U., Požek, E., Fenk, R. R., Besemer, B., Hanoun, C., Schroers, R., von Metzler, I., Hänel, M., Mann, C., et al. (2024) · Journal of Clinical Oncology · doi:10.1200/jco-24-02266 · Cited by 92
Self-citationNCCN Guidelines® Insights: Multiple Myeloma, Version 1.2025
Kumar, S. K., Callander, N. S., Adekola, K., Anderson, L. D., Jr., Baljević, M., Baz, R., Campagnaro, E. L., Costello, C. L., D'Angelo, C. R., Derman, B. A., et al. (2025) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2025.0023 · Cited by 70
Self-citationNeri, P., Leblay, N., Lee, H., Gullà, A., Bahlis, N. J., & Anderson, K. C. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-024-00913-y · Cited by 41
Minimal Residual Disease as an Early Endpoint for Accelerated Drug Approval in Myeloma: A Roadmap
Landgren, O., & Devlin, S. M. (2024) · Blood Cancer Discovery · doi:10.1158/2643-3230.bcd-24-0292 · Cited by 47
The burden of multiple myeloma in China: Trends from 1990 to 2021 and forecasts for 2050
Dou, X., Duan, G., Zhong, Y., Liu, Y., Peng, N., Lei, W., Qi, J., Zhou, M., Zhang, X., & Lu, J. (2025) · Cancer Letters · doi:10.1016/j.canlet.2025.217440 · Cited by 39
Ntanasis‐Stathopoulos, I., Filippatos, C., Ntanasis‐Stathopoulos, A., Malandrakis, P., Kastritis, E., Tsitsilonis, O., Dimopoulos, M. A., Terpos, E., & Gavriatopoulou, M. (2025) · American Journal of Hematology · doi:10.1002/ajh.27582 · Cited by 32
“In total, 36 articles with results from 29 randomized controlled trials were included [2, 3, 19– 52 ].”
Self-citationMateos, M., Miguel, J. F. S., Cavo, M., Suzuki, K., Jakubowiak, A. J., Knop, S. T., Doyen, C., Lúcio, P., Nagy, Z., Pour, L., et al. (2025) · The Lancet Oncology · doi:10.1016/s1470-2045(25)00018-x · Cited by 37
Self-citationEuropean Myeloma Network Group review and consensus statement on primary plasma cell leukemia
Musto, P., Engelhardt, M. M., van de Donk, N. W. C. J., Gay, F., Terpos, E., Einsele, H., de Larrea, C. F., Sgherza, N., Bolli, N., Katodritou, E., et al. (2025) · Annals of Oncology · doi:10.1016/j.annonc.2025.01.022 · Cited by 33
Self-citationEbraheem, M. S., Chakraborty, R., Rochwerg, B. N., Visram, A., Mohyuddin, G. R., Venner, C. P., Sandhu, I., McCurdy, A. B. R., Facon, T. T. F., Mateos, M., et al. (2024) · Blood Advances · doi:10.1182/bloodadvances.2024014139 · Cited by 30
“We also searched the abstracts from American Society of Clinical Oncology 2024 because we became aware that the pivotal trial IMROZ 8,9 would be presented (details also extracted from the concurrent publication of the results 9 ).”
Self-citationAilawadhi, S., Špıčka, I., Spencer, A. G., Lu, J., Oriol, A., Ling, S., Schjesvold, F. H., Berkovits, A., Hus, M., Li, C., et al. (2025) · Journal of Clinical Oncology · doi:10.1200/jco-25-00744 · Cited by 25
Self-citationLasa, M., González, C., Notarfranchi, L., Zherniakova, A., Alignani, D., Burgos, L., Calasanz, M. J., Rodríguez‐Otero, P., Pérez, J. J., Gómez, C., et al. (2025) · Blood · doi:10.1182/blood.2025029234 · Cited by 17
Askeland, F. B., Haukås, E., Slørdahl, T. S., Klostergaard, A., Alexandersen, T., Osnes, L., Lysén, A., Abdollahi, P., Nielsen, L. K., Hermansen, E., et al. (2025) · The Lancet Haematology · doi:10.1016/s2352-3026(24)00347-8 · Cited by 44
Besliu, C., Tănase, A., Rotaru, I., Espinoza, J., Vidal, L., Poelman, M., Juan, M., de Larrea, C. F., & Saini, K. S. (2025) · Cancers · doi:10.3390/cancers17030525 · Cited by 17
“…NDMM with the Dara-VRd regimen in the PERSEUS trial [26] and 74.7% in transplant-ineligible NDMM with Isa-VRd in the IMROZ trial [27], while in patients with lenalidomide-refractory disease, the ≥ CR rate was 73.1% with CAR T cell therapy ciltacabtagene autoleucel (Cilta-cel) in…”
InfluentialBanerjee, R. K., Sexton, R., Cowan, A. J., Rosenberg, A. S., Ailawadhi, S., Rajkumar, S. V., Kumar, S. K., Dispenzieri, A. A., Lonial, S., Durie, B. G. M., et al. (2024) · Blood · doi:10.1182/blood.2024025939 · Cited by 13
Self-citationAntibody-Based Immunotherapies for the Treatment of Hematologic Malignancies
Jureczek, J., Kałwak, K., & Dzięgiel, P. (2024) · Cancers · doi:10.3390/cancers16244181 · Cited by 16
Multiple Myeloma: Improved Outcomes Resulting from a Rapidly Expanding Number of Therapeutic Options
Mettias, S., ElSayed, A., Moore, J., & Berenson, J. R. (2025) · Targeted Oncology · doi:10.1007/s11523-024-01122-4 · Cited by 15
Adegbite, B. O., Tan, C. R. C., Shekarkhand, T., Firestone, R., Jurgens, E. M., Miller, K., Lesokhin, A. M., Shah, G. L., Korde, N., Rajeeve, S., et al. (2025) · Blood Advances · doi:10.1182/bloodadvances.2025015973 · Cited by 16
Lu, R., Ren, L., Fei, X., Liu, S., Gao, Y., Hou, J., Wang, C., Liu, P., Zhu, C., Wang, X., et al. (2025) · Advanced Science · doi:10.1002/advs.202505762 · Cited by 19
Ocio, E. M., Perrot, A., Moreau, P., Mateos, M., Bringhen, S., Martínez‐López, J., Karlin, L., Wang, S., Oprea, C., Li, Y., et al. (2024) · HemaSphere · doi:10.1002/hem3.70041 · Cited by 8
Self-citationIberdomide, ixazomib and dexamethasone in elderly patients with multiple myeloma at first relapse
Touzeau, C., Leleu, X. P., Tiab, M., Macro, M., Perrot, A., Gay, J., Chateleix, C., Moreau, S., Karlin, L., Jacquet, C., et al. (2025) · British Journal of Haematology · doi:10.1111/bjh.19978 · Cited by 13
Self-citationNovel Treatment Options for Multiple Myeloma
Portuguese, A. J., Banerjee, R. K., Chen, G. Z., Reddi, S., & Cowan, A. J. (2025) · JCO Oncology Practice · doi:10.1200/op-24-00752 · Cited by 17
Treatment of myeloma bone disease: When, how often, and for how long?
Gundesen, M. T., Schjesvold, F. H., & Lund, T. (2025) · Journal of bone oncology · doi:10.1016/j.jbo.2025.100680 · Cited by 12
“While relevant at the time, the induction and maintenance were suboptimal compared to the current SOC which often include combinations of bortezomib, lenalidomide, dar-atumumab and lenalidomide [48,49].”
Management recommendations for kidney transplantation in patients with plasma cell dyscrasia
Murakami, N., Blosser, C. D., Webber, A. B., Gupta, G., Singh, N., Boppana, S., Master, S. R., Parasuraman, R. K., Campagnaro, E. L., Java, A., et al. (2025) · Kidney International · doi:10.1016/j.kint.2025.07.011 · Cited by 11
Treatment of Multiple Myeloma: ASCO–Ontario Health (Cancer Care Ontario) Living Guideline
Hicks, L. K., Messersmith, H. J., Hadidi, S. S. A. A., Banerjee, R. K., Derman, B. A., Kumar, S. K., Wildes, T. M., Bal, S., Bhella, S., Chmielewski, C., et al. (2026) · Journal of Clinical Oncology · doi:10.1200/jco-25-02587 · Cited by 17
Self-citationBCMA-directed therapy for early relapsed and/or refractory multiple myeloma
van de Donk, N. W. C. J., & Zweegman, S. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-024-00927-6 · Cited by 8
Rubinstein, S. M., Mohsin, A., Banerjee, R., Ma, W., Mishra, S., Kwok, M., Yang, P. C., Warner, J. L., & Cowan, A. J. (2025) · Frontiers in Digital Health · doi:10.3389/fdgth.2025.1569554 · Cited by 12
“…synopsis for transplant-ineligible newly diagnosed multiple myeloma (MM) may identify quadruplet induction as the standard of care based on recent trials without adding that older and frailer patients (for whom quadruplet induction may be inappropriate) were excluded from these trials (9).”
Minimal Residual Disease Negativity as the Primary Goal of Multiple Myeloma Therapy
Cooperrider, J. H., & Derman, B. A. (2025) · Drugs · doi:10.1007/s40265-025-02232-7 · Cited by 9
“In the IMROZ trial, the rate of MRD 10 −5 was 58% for Isa-VRd compared with 43.6% for VRd, with a near doubling of sustained MRD negativity of 47% for Isa-VRd versus 24% for VRd [92].”
InfluentialCani, L., Parikh, R., Joseph, N. S., Gupta, V. A., Hofmeister, C. C., Kaufman, J. L., Nooka, A. K., Lonial, S., & Mina, R. (2026) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2026.03.003 · Cited by 8
Gay, F., Roeloffzen, W., Dimopoulos, M. A., Rosiñol, L., van der Klift, M., Mina, R., Oriol, A., Katodritou, E., Wu, K. L., Rodríguez‐Otero, P., et al. (2026) · Nature Medicine · doi:10.1038/s41591-026-04282-0 · Cited by 12
“nature medicine https://doi.org/10.1038/s41591-026-04282-0”
InfluentialSelf-citationMinimal residual disease in multiple myeloma
Moukalled, N. M., Malard, F., Bazarbachi, A. A., & Mohty, M. (2024) · La Presse Médicale · doi:10.1016/j.lpm.2024.104261 · Cited by 7
Self-citationCurrent Treatment Strategies for Multiple Myeloma at First Relapse
Mavrothalassitis, E., Triantafyllakis, K., Malandrakis, P., Gavriatopoulou, M., Kleber, M., & Ntanasis‐Stathopoulos, I. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14051655 · Cited by 7
“This is further reinforced by the positive results of the IMROZ and the GMMG-HD7 trial that introduce isatuximab-based combinations in the upfront treatment for transplant-ineligible and -eligible patients with MM [50,51].”
Mateos, M., Paiva, B., Cedena, M., Puig, N., Sureda, A. M., González‐Calle, V., Oriol, A., Ocio, E. M., Rosiñol, L., Montes, Y. G., et al. (2025) · The Lancet Haematology · doi:10.1016/s2352-3026(25)00143-7 · Cited by 11
Wang, Y., Yu, W., Wang, X., Zhao, Q., Lei, Q., Li, A., Liu, S., Wang, T., Yang, L., & Zhang, Y. (2025) · Advanced Science · doi:10.1002/advs.202506995 · Cited by 11
Human preclinical multiple myeloma in vitro models for disease modeling and therapy screening
Ybarra, M., Lee, J., Chen, Y.-Y., Lin, J., Zhao, J., & Ma, C. (2025) · Journal of Biological Engineering · doi:10.1186/s13036-025-00570-4 · Cited by 8
“…immunomodulatory drugs (IMiDs) that can amplify immune response, monoclonal antibodies to directly induce apoptosis, and other immunotherapy treatments such as chimeric antigen receptor (CAR) T-cell therapy that targets MM specific markers such as B-cell maturation antigen (BCMA) [25–34].”
Terpos, E., Gavriatopoulou, M., Ntanasis‐Stathopoulos, I., Malandrakis, P., Fotiou, D., Kanellias, N., Migkou, M., Theodorakakou, F., Spiliopoulou, V., Solia, E., et al. (2025) · Blood · doi:10.1182/blood.2025031629 · Cited by 7
Self-citationToward a cure for multiple myeloma within a decade
Mohty, M., Malard, F., Facon, T. T. F., & Harousseau, J. (2026) · Blood Cancer Journal · doi:10.1038/s41408-026-01461-7 · Cited by 8
“…in transplant ineligible patients in the IMROZ trial, IsaVRd achieved signi fi cantly higher MRD negativity rates (10 ⁻ ⁶ ) compare to VRd, translating in an estimated PFS at 60 months of 63.2% in the IsaVRd (Isatuximab + VRD) group, as compared with 45.2% in the VRd group (P 0.001) [20].”
InfluentialSelf-citationHansen, D. K., Gautam, S., Lafeuille, M., Rossi, C., Moore, B., Tardif‐Samson, A., Thompson‐Leduc, P., Fu, A. Z., Cortoos, A., Kaila, S., et al. (2024) · Cancer Medicine · doi:10.1002/cam4.70308 · Cited by 9
Osama, M., Khan, M. H., Khan, S., Hussain, A., Tahir, A., Ullah, M., Afridi, A., Ullah, U., & Rehman, W. U. (2025) · Therapeutic Advances in Hematology · doi:10.1177/20406207251314289 · Cited by 8
Avello, N. S., Pajares, P. C., Cordero, P., Suzan, F., & Barlas, C. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1547108 · Cited by 11
“Based on the results of the Phase 3 IMROZ trial (NCT03319667), IV Isa has been recently approved in the United States in combination with bortezomib, lenalidomide, and dexamethasone for the treatment of patients with newly diagnosed MM not eligible for an autologous stem cell transplant (8, 12).”
Gay, F., Zamagni, E., Cole, C. E., Scheid, C., Hultcrantz, M. L., Chorąży, J., Iheanacho, I., Pandey, A., Bitetti, J., Boytsov, N. N., et al. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1550644 · Cited by 10
Self-citationNovellis, D. D., Scala, P., Giudice, V., & Selleri, C. (2025) · Cells · doi:10.3390/cells14110776 · Cited by 7
“However, in the phase III IMROZ trial, isatuximab plus VRD (isa-VRD) has not shown improved outcomes in patients with high-risk cytogenetic features and older age [88], as well as daratumumab plus VRD in the CEPHEUS study [89].”
The past, present, and future of myeloma staging and risk prognostication
Baysal, M., Julian, K. L., Sborov, D. W., Godara, A., McClune, B. L., Lohr, J. G., Fortuna, G. G., & Mohyuddin, G. R. (2025) · The Oncologist · doi:10.1093/oncolo/oyaf299 · Cited by 7
Moore, D. C., Elsey, G., McElwee, J., & Atrash, S. (2025) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2025.2595122 · Cited by 7
Current State of Evidence on Definitions and Management of High-Risk Multiple Myeloma
Lal, B. M., van Rhee, F., & Hadidi, S. A. (2025) · Current Oncology Reports · doi:10.1007/s11912-025-01639-5 · Cited by 8
“However, the PFS benefit was not seen in patients with high-risk disease defined as one or more of del(17p), t(4;14), t(14;16), or > 3 copies of 1q21 (HR: 0.97, 95% CI 0.48–1.96), or in patients with HRCA with 1q21+ (HR: 0.49, 95% CI: 0.19–1.29) [112].”
InfluentialSurvival, Years of Life Lost and Attrition Rates in Multiple Myeloma Patients in France
Perrot, A., RAGUIDEAU, F., Denis, H., Prodel, M., Javelot, M., Pierrès, M., & Touzeau, C. (2025) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2025.03.004 · Cited by 6
Kikuchi, T., Watanabe, M., Tsukada, N., Matsumoto, C., Nomura‐Yogo, M., Kunisada, K., Sawada, H., Sato, K., Takei, T., Ogura, M., et al. (2025) · Transplant Infectious Disease · doi:10.1111/tid.70040 · Cited by 6
Self-citationNtanasis‐Stathopoulos, I., Filippatos, C., Malandrakis, P., Koutoulidis, V., Kastritis, E., Terpos, E., Dimopoulos, M. A., & Gavriatopoulou, M. (2025) · Cancers · doi:10.3390/cancers17121943 · Cited by 7
“The recently published IMROZ study highlighted the benefits of combining isatuximab with bortezomib, lenalidomide, and dexamethasone (VRd), showing improved progression-free survival and deeper responses in NDMM patients, further supporting its role as a viable option in the first-line setting [18].”
Self-citationChalayer, É., Frère, C., Daguenet, É., Lecompte, T., Tardy, B., Bounouara, I., Sapet, M., Bobin, A., Harel, S., Decaux, O., et al. (2025) · Journal of Thrombosis and Haemostasis · doi:10.1016/j.jtha.2025.06.012 · Cited by 5
Self-citationMartino, E. A., Caridà, G., Lofaro, D., Bruzzese, A., Labanca, C., Mendicino, F., Lucia, E., Olivito, V., Puccio, N., Neri, A., et al. (2025) · ESMO Open · doi:10.1016/j.esmoop.2025.105514 · Cited by 7
Askari, E., Dispenzieri, A. A., Buadi, F. K., Hayman, S. R., Gertz, M. A., Kapoor, P., Gonsalves, W. I., Kourelis, T., Dingli, D., Warsame, R. M., et al. (2025) · Blood Cancer Journal · doi:10.1038/s41408-025-01340-7 · Cited by 7
“The treatment landscape in newly diagnosed MM has undergone a remarkable evolution with the introduction of many immunotherapies, which has led to deeper responses and better survival outcomes [4 – 8].”
Meads, M. B., Zhao, X., Noyes, D. R., Sudalagunta, P. R., Achille, A., Zhang, C. H., Canevarolo, R. R., Silva, M. J., Magaletti, D. M., DeAvila, D., et al. (2025) · Blood · doi:10.1182/blood.2025029921 · Cited by 6
Parmar, G., Capra, M., Seguro, F. S., Hungria, V., Dimopoulos, M. A., Delimpasi, S., Minařík, J., Špıčka, I., Pour, L., Marques, H., et al. (2025) · Blood Cancer Journal · doi:10.1038/s41408-025-01436-0 · Cited by 7
Self-citationContinuous or Fixed-Duration Maintenance Therapy in Multiple Myeloma
Kumar, S. K., Jacobus, S. J., Cohen, A. D., Weiss, M., Callander, N. S., Singh, A., Parker, T. L., Green, M., Thertulien, R., Parsons, B. M., et al. (2026) · New England Journal of Medicine · doi:10.1056/nejmoa2600157 · Cited by 7
Self-citationMaintenance Therapy in the Era of Quadruplets for Multiple Myeloma: When, What, and for How Long?
Mian, H. S., & Costa, L. J. (2025) · American Journal of Hematology · doi:10.1002/ajh.70002 · Cited by 5
Isatuximab for the treatment of multiple myeloma: current clinical advances and future directions
Richardson, P. G. G., O’Donnell, E. K., O’Gorman, P., Leypoldt, L. B., Laubach, J. P., Gay, F., Leleu, X. P., Facon, T. T. F., Moreau, P., Dimopoulos, M. A., et al. (2025) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2025.2532446 · Cited by 5
“Isatuximab is a mAb that binds a specific CD38 epitope and demonstrated a profound efficacy benefit across multiple Phase 2 and 3 trials in RRMM and NDMM [11,12,14–25].”
InfluentialSelf-citationKotb, R. R., Geirnaert, M., Rimmer, E. K., Dao, V., Kasian, J., Minuk, L. A., & Landego, I. (2025) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2025.01.022 · Cited by 4
Chen, W., Cai, Z., Chim, J. C., Chng, W. J., Du, J., Fu, C., Hanamura, I., Hou, J. M., Huang, J., Ishida, T., et al. (2025) · Clinical Hematology International · doi:10.46989/001c.133682 · Cited by 8
Self-citationMolecular and immunological determinants of long-term survival in multiple myeloma
Kasomva, K., Yadav, K., Janz, S., Dhakal, B., & Rao, S. (2025) · Blood Advances · doi:10.1182/bloodadvances.2025016829 · Cited by 4
“28,29 Although promising, managing toxicities, especially in older patients, remains critical to balancing safety and efficacy.”
Choosing the optimal maintenance strategy in multiple myeloma
Puliafito, B. R., Cirstea, D. D., & Raje, N. S. (2025) · Hematology · doi:10.1182/hematology.2025000732 · Cited by 4
Gan, X., Li, L., Zhang, L., Zheng, Y., Niu, T., & Yu, Z. (2026) · Targeted Oncology · doi:10.1007/s11523-026-01199-z · Cited by 4
How I treat plasma cell leukemia
Hadidi, S. A., van Rhee, F., & Anderson, L. D. (2026) · Blood · doi:10.1182/blood.2025032145 · Cited by 4
SOHO State of the Art Updates and Next Questions | Late/Deferred ASCT in Myeloma
Mo, C. C., Liu, Y., Hartley-Brown, M. A., Nadeem, O., Midha, S., & Richardson, P. G. G. (2025) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2025.06.003 · Cited by 4
Yan, W., Du, C., Lv, R., Zou, H., Zhang, S., Yu, T., Yan, Y., Zhang, Y., Peng, S., Wang, T., et al. (2026) · Journal of Clinical Oncology · doi:10.1200/jco-25-01969 · Cited by 7
Xiong, Y., Liang, S., Tang, W., Zhang, L., Zheng, Y., Pan, L., & Niu, T. (2024) · Cancer Medicine · doi:10.1002/cam4.70193 · Cited by 3
Lenalidomide, ixazomib, or daratumumab maintenance therapy in multiple myeloma
Lai, E. E. N., Soon, Y. Y., Lee, A. R. Y. B., Wong, S. Y., Soekojo, C. Y., Ooi, M. G. M., Chng, W. J., & Mel, S. D. (2024) · Blood Neoplasia · doi:10.1016/j.bneo.2024.100042 · Cited by 4
Treatment of elderly and frail myeloma patients
Shih, S. C.-M., Visram, A., & Mian, H. S. (2024) · La Presse Médicale · doi:10.1016/j.lpm.2024.104266 · Cited by 4
Mian, H. S., Visram, A., Shih, S. C.-M., Trudel, S., Hay, A. E., LeBlanc, R., Sébag, M., Kaedbey, R., Stakiw, J., Sandhu, I., et al. (2025) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2025.01.010 · Cited by 3
Kort, J., Naleid, N., Oley, F., Ignatz-Hoover, J. J., Margevicius, S. P., Fu, P., Malek, E., & Cooper, B. (2025) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2025.02.004 · Cited by 3
Encinas, C., Blanchard, M. J., Alonso, R., Hernández‐Rivas, J., Tamayo, R. R., Machado-Vílchez, M., Martínez‐López, J., & Mateos, M. (2025) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2025.06.012 · Cited by 9
Foster, L. H., Anderson, L. D., Chung, A., Chaulagain, C. P., Pettijohn, E. M., Cowan, A. J., Costello, C. L., Larson, S., Sborov, D. W., Shain, K. H., et al. (2025) · Blood Cancer Journal · doi:10.1038/s41408-025-01355-0 · Cited by 4
Endless possibilities and how to exploit them? What is the optimal treatment sequence?
Chakraborty, R., Bhutani, D., & Lentzsch, S. (2025) · Hematology · doi:10.1182/hematology.2025000760 · Cited by 3
Mina, R., Antonioli, E., Barilà, G., Bolli, N., Botta, C., Furlan, A., Liberatore, C., Martello, M., Móre, S. M. C., Oliva, S., et al. (2025) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2025.12.016 · Cited by 3
Self-citationPast, Present, and Future of Dexamethasone in Multiple Myeloma and AL Amyloidosis
Banerjee, R. K., King, T., Faiman, B., Harding, S., Rosenberg, A. S., Sanchorawala, V., Mikhael, J. R., & Cowan, A. J. (2026) · Journal of Clinical Oncology · doi:10.1200/jco-25-01713 · Cited by 4
Costa, B. A., Costa, T. A., Chagas, G. C. L., Mouhieddine, T. H., Richter, J. R., Usmani, S. Z., Mailankody, S., Rajeeve, S., & Hashmi, H. (2024) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2024.09.008 · Cited by 3
Costa, L. J., Gay, F., Landgren, O., Mateos, M., Moreau, P., Touzeau, C., Ertel, F., McFadden, I., Najdi, R., & Weisel, K. C. (2025) · Annals of Hematology · doi:10.1007/s00277-024-06143-7 · Cited by 3
“Investigations into the use of VRd plus anti-CD38 quadruplet regimens without transplant for selected patients were recently published [62, 63].”
Self-citationBai, H., Zhang, C., Zhao, A., Tang, W., & Zhang, L. (2025) · Therapeutic Advances in Hematology · doi:10.1177/20406207251319593 · Cited by 3
Challenges in Multiple Myeloma Therapy in Older and Frail Patients
Aureli, A., Marziani, B., Sconocchia, T., Pasqualone, G., Franceschini, L., Spagnoli, G. C., Venditti, A., & Sconocchia, G. (2025) · Cancers · doi:10.3390/cancers17060944 · Cited by 5
“Facon et al. demonstrated that the addition of the anti-CD38 monoclonal antibody isatuximab to the VRd regimen slowed disease progression in patients with MM from 18 to 80 years of age [44].”
InfluentialBenda, M. A., Reimann, P., Bletzacher, E., Muendlein, A., Bernhard, B. S., Hartmann, B. L., Huynh, M., Gasser, K., Zojer, N., Lang, T., et al. (2025) · Cancers · doi:10.3390/cancers17081261 · Cited by 3
“At the last EHA in 2024, long-term data from the IMROZ trial were presented on quadruple therapy in fit, non-transplantable patients [7–10].”
Current and Future Directions of Immunotherapies in Multiple Myeloma
Biltibo, E. A., Surapaneni, M., Hadidi, S. A., Suvannasankha, A., & Jayani, R. (2025) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk-25-473316 · Cited by 5
Shameli, A., Catey, T., Woodings, V., Koepke, O., Fromm, J. R., & Cherian, S. (2025) · British Journal of Haematology · doi:10.1111/bjh.20218 · Cited by 25
“15 While daratumum-ab's effect on PC FC results has been extensively studied, there is very limited such information about isatuximab, and the optimal panel to identify PCs in this setting is not clear.”
Moore, S. E., Miller, H., Parrish, C., Seymour, F., Miller, L. J., Chandler, T., Land, J., Karpha, I., Brearton, G., Thompson, S., et al. (2025) · British Journal of Haematology · doi:10.1111/bjh.70041 · Cited by 6
“…superiority of IsaVRD was confirmed in both studies, with the 60-month PFS in the IMROZ study reported as 63% in the IsaVRD group compared to 45.2% for the control group, 53 the paucity of patients over 80 years old limited the extent to which this regimen could be recommended for older patients.”
InfluentialLin, Z., Dong, R., Zhang, W., Liu, R., Fu, B., & He, A. (2025) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2025.2512031 · Cited by 3
“Finally, a total of 13 articles involving 8 RCTs were included (Figure 1) [12,15,18,19,34–42].”
Gupta‐Werner, N., Khare, V., Macomson, B., & Medhekar, R. (2025) · Journal of health economics and outcomes research · doi:10.36469/001c.141714 · Cited by 3
Analysis of Multiple Myeloma Drug EfficacyPreprint
Matov, A. (2024) · medRxiv · doi:10.22541/au.172495995.58510565/v1 · Cited by 8
Caroni, F., Sammartano, V., Pacelli, P., Sicuranza, A., Malchiodi, M., Dragomir, A., Ciofini, S., Raspadori, D., Bocchia, M., & Gozzetti, A. (2025) · Pharmaceuticals · doi:10.3390/ph18020159 · Cited by 3
“The efficacy of Isa-VRd in TIE NDMM patients was demonstrated in the phase 3 BENEFIT and IMROZ trials [77,78].”
Functional Cure as a New Concept of Therapy for Multiple Myeloma
Семочкин, С. В. (2025) · Clinical oncohematology · doi:10.21320/2500-2139-2025-18-2-105-120 · Cited by 3
Rodríguez‐Otero, P., Voorhees, P. M., Boccadoro, M., Laubach, J. P., Einsele, H., Sborov, D. W., Dimopoulos, M. A., Broijl, A., Mina, R., Spencer, A. G., et al. (2025) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2025.04.007 · Cited by 2
Self-citationAdvances in NK cell therapy for multiple myeloma
Liu, N., Zeng, Y., Wang, Y., Wang, C., Li, N., & Xu, J. (2025) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2025.101639 · Cited by 3
Alotaibi, G., Saleh, A. S. A., Alhejazi, A., Alahmadi, M. D., Motabi, I., Alsharif, F. Z., Alamer, A., Abduljalil, O., Tailor, I. K., Marei, M. A., et al. (2025) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2025.06.005 · Cited by 3
Revolutions at the frontline of multiple myeloma treatment: lessons and challenges to finding a cure
Kort, J., Rivera, A., Senigarapu, S., & Driscoll, J. J. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1578529 · Cited by 3
Bringhen, S., Cani, L., Antonioli, E., Derudas, D., Fazio, F., Larocca, A., Ronconi, S., Cellini, C., Falcone, A. P., Accardi, F., et al. (2025) · The Lancet Haematology · doi:10.1016/s2352-3026(25)00162-0 · Cited by 4
Treatment of transplant-ineligible multiple myeloma
Jung, J. (2025) · Blood Research · doi:10.1007/s44313-025-00102-5 · Cited by 3
“In both groups, VRd was administered according to the same scheme used in the SWOG S0777 trial [31].”
Rizzello, I., Sacchetti, I., Barbato, S., Solli, V., Stefanoni, P., Cani, L., Quaresima, M., Belotti, A., Sgherza, N., Gentile, M., et al. (2025) · Clinical and Experimental Medicine · doi:10.1007/s10238-025-01956-w · Cited by 4
Self-citationCan I stop my treatment, doctor? Is MRD-guided therapy ready for prime time?
Derman, B. A. (2025) · Hematology · doi:10.1182/hematology.2025000761 · Cited by 2
Filho, J. T. D. S., Cantadori, L. O., Crusoé, E. D. Q., Hungria, V., & Maiolino, Â. (2025) · Blood Cancer Journal · doi:10.1038/s41408-025-01413-7 · Cited by 7
“Figure 1 summarizes the ef fi cacy outcomes ( ≥ CR, PFS and OS) from all included trials.”
Influential
Metadata
- Authors
- Facon, T., Dimopoulos, M.-A., Leleu, X. P., Beksac, M., Pour, L., Hájek, R., Liu, Z., Minarik, J., Moreau, P., Romejko-Jarosinska, J., Spicka, I., Vorobyev, V. I., Besemer, B., Ishida, T., Janowski, W., Kalayoglu-Besisik, S., Parmar, G., Robak, P., Zamagni, E., Goldschmidt, H., Martin, T. G., Manier, S., Mohty, M., Oprea, C., Brégeault, M.-F., Macé, S., Berthou, C., Bregman, D., Klippel, Z., & Orlowski, R. Z.
- Affiliations
- Inserm (FR)
- From the Department of Hematology, Centre Hospitalier Universitaire (CHU) de Lille, University of Lille, Lille (T.F., S. Manier), the French National Academy of Medicine (T.F.), and the Department of Hematology, Hôpital Saint-Antoine, Sorbonne University and INSERM (M.M.), Paris, Service d’Hématologie et Thérapie Cellulaire, CHU and Centre d’Investigation Clinique INSERM Unité 1402, Poitiers (X.P.L.), the Department of Hematology, University Hospital Hôtel-Dieu, Nantes (P.M.), and Sanofi, Research and Development, Vitry-sur-Seine (C.O., M.-F.B., S. Macé, C.B.) — all in France; the Plasma Cell Dyscrasia Unit, Department of Clinical Therapeutics, National and Kapodistrian University of Athens, Athens (M.-A.D.); the Department of Hematology, Ankara University, and the Istinye University Ankara Liv Hospital, Ankara (M.B.), and the Department of Internal Medicine, Istanbul Medical Faculty, Istanbul University, Istanbul (S.K.-B.) — all in Turkey; the Department of Internal Medicine, Hematology, and Oncology, Uni...
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2024-10-31
- Volume
- 391
- Issue
- 17
- Pages
- 1597-1609
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4399304831
- Semantic Scholar
- a45e6cd60318735bf0f85aba849da20117440058
- Cited by
- 284
- References
- 30
- Citations by year
- 2026: 100 · 2025: 155 · 2024: 29
- FWCI
- 87.72
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion)
- Funders
- Sanofi
- Topics
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Health Sciences › Medicine › Oncology › Bone health and treatments
- Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
- Keywords
- isatuximab, bortezomib, lenalidomide, dexamethasone, multiple myeloma, newly diagnosed multiple myeloma, anti-CD38 monoclonal antibody, progression-free survival, complete response, minimal residual disease, transplant-ineligible patients, first-line therapy
- MeSH terms
- Bortezomib, Lenalidomide, Progression-Free Survival, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Dexamethasone, Female, Humans, Male, Middle Aged, Multiple Myeloma, Neoplasm, Residual, Kaplan-Meier Estimate, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.